The build-out is already underway and is anticipated to be completed in 2022. The facility will support NK and CAR-NK cell production for Artiva's pipeline development and clinical trial supply for the treatment of solid and hematological cancers, the company said.

Artiva's San Diego NK cell therapy research and GMP manufacturing facility. Image courtesy of Artiva Biotherapeutics.

The expansion builds on Artiva's current capabilities at its partner GC LabCell's facility in Korea.

CAR-NK cells hold promise for solid tumors
A new cancer immunotherapy that leverages the ability of natural killer (NK) cells to discriminate between cancer and normal cells has shown promise in...

Catamaran Bio, Bio-Techne expand CAR-NK cell collaboration
Catamaran Bio and Bio-Techne have expanded their collaboration on the development of cell engineering and cell process technologies for Catamaran's manufacturing...

Advancing from CAR T-cell therapies to modified NK cell therapies
Chimeric antigen receptor (CAR) T-cell therapies have quickly become promising candidates for the treatment of many cancers. However, other immune cell...

Artiva nabs $120M for NK cell therapies
Artiva Biotherapeutics has closed $120 million in financing to advance its natural killer (NK) cell therapy development programs and expand ongoing research...

Artiva, Merck to develop CAR NK cell therapies
Artiva Biotherapeutics and Merck have signed an agreement to develop chimeric antigen receptor (CAR) natural killer (NK) cell therapeutics for solid tumors.